Prof. Dr. med. Pietro Vernazza
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
Wolbers M, Bucher H, Kaufmann G, Bernasconi E, Vernazza P, Hasse B, Cavassini M, Furrer H, Hirschel B, Battegay M, Swiss HIV Cohort Study. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy 2007; 12:889-97.
Jan 1, 2007CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
Jan 1, 2007Antiviral therapy 2007; 12:889-97
Wolbers Marcel, Bucher Heiner C, Kaufmann Gilbert, Bernasconi Enos, Vernazza Pietro, Hasse Barbara, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, Battegay Manuel, Swiss HIV Cohort Study
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
Simcock M, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher H, Battegay M, Koller M, Moirandat-Rytz S, Terziroli B, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson J, Bernasconi E, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy 2007; 12:931-9.
Jan 1, 2007Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
Jan 1, 2007Antiviral therapy 2007; 12:931-9
Simcock Mathew, Furrer Hansjakob, Hirschel Bernard, Vernazza Pietro, Sendi Pedram, Rickenbach Martin, Bucher Heiner C, Battegay Manuel, Koller Michael T, Moirandat-Rytz Sophie, Terziroli Benedetta, Blasko Monika, Karrer Urs, Bertisch Barbara, Pless Miklos, Blumer Liisa, Vora Samir, Robinson James Owen, Bernasconi Enos, Swiss HIV Cohort Study
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
Keiser O, Furrer H, Telenti A, Rickenbach M, Vernazza P, Bernasconi E, Hirschel B, Hirsch H, Opravil M, Fellay J, Swiss HIV Cohort Study. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antiviral therapy 2007; 12:1157-64.
Jan 1, 2007Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
Jan 1, 2007Antiviral therapy 2007; 12:1157-64
Keiser Olivia, Furrer Hansjakob, Telenti Amalio, Rickenbach Martin, Vernazza Pietro, Bernasconi Enos, Hirschel Bernard, Hirsch Hans H, Opravil Milos, Fellay Jacques, Swiss HIV Cohort Study
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Wolbers M, Simcock M, Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy 2007; 12:1165-73.
Jan 1, 2007Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Jan 1, 2007Antiviral therapy 2007; 12:1165-73
Fux Christoph A, Furrer Hansjakob, Elzi Luigia, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Hirschel Bernard, Bucher Heiner C, Wolbers Marcel, Simcock Mathew, Swiss HIV Cohort Study
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine 2006; 7:404-10.
Sep 1, 2006Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Sep 1, 2006HIV medicine 2006; 7:404-10
Glass T R, Bucher H C, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza Pietro, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
Ananworanich J, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Bernasconi E, Vernazza P, Nüesch R, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-65.
Aug 5, 2006CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
Aug 5, 2006Lancet 2006; 368:459-65
Ananworanich Jintanat, Leduc Dominic, Satchell Claudette, Yerly Sabine, Perrin Luc, Hill Andrew, Perneger Thomas, Phanuphak Praphan, Furrer Hansjakob, Cooper David, Ruxrungtham Kiat, Hirschel Bernard, Staccato Study Group, Bernasconi Enos, Vernazza Pietro, Nüesch Reto, Gayet-Ageron Angèle, Le Braz Michelle, Prasithsirikul Wisit, Chetchotisakd Ploenchan, Kiertiburanakul Sasisopin, Munsakul Warangkana, Raksakulkarn Phitsanu, Tansuphasawasdikul Somboon, Sirivichayakul Sunee, Cavassini Matthias, Karrer Urs, Genné Daniel, Swiss HIV Cohort Study
Stable virulence levels in the HIV epidemic of Switzerland over two decades
Müller V, Bonhoeffer S, Günthard H, Vernazza P, Bernasconi E, Telenti A, Furrer H, Klimkait T, Perrin L, Ledergerber B, Swiss HIV Cohort Study. Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS (London, England) 2006; 20:889-94.
Apr 4, 2006Stable virulence levels in the HIV epidemic of Switzerland over two decades
Apr 4, 2006AIDS (London, England) 2006; 20:889-94
Müller Viktor, Bonhoeffer Sebastian, Günthard Huldrych F, Vernazza Pietro, Bernasconi Enos, Telenti Amalio, Furrer Hansjakob, Klimkait Thomas, Perrin Luc, Ledergerber Bruno, Swiss HIV Cohort Study
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
Glass T, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, De Geest S, Bucher H. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2006; 41:385-92.
Mar 1, 2006Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
Mar 1, 2006Journal of acquired immune deficiency syndromes (1999) 2006; 41:385-92
Glass Tracy R, Battegay Manuel, Hirschel Bernard, Cavassini Matthias, Bernasconi Enos, Furrer Hansjakob, Rickenbach Martin, Vernazza Pietro, Weber Rainer, De Geest Sabina, Bucher Heiner C
HIV-discordant couples and parenthood: how are we dealing with the risk of transmission?
Vernazza P, Hollander L, Semprini A, Anderson D, Duerr A. HIV-discordant couples and parenthood: how are we dealing with the risk of transmission?. AIDS (London, England) 2006; 20:635-6.
Feb 28, 2006HIV-discordant couples and parenthood: how are we dealing with the risk of transmission?
Feb 28, 2006AIDS (London, England) 2006; 20:635-6
Vernazza Pietro, Hollander Lital, Semprini Augusto E, Anderson Deborah J, Duerr Ann
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
Nov 1, 2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Nov 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study
Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial
Tillmann H, Lundgren J, Dragsted U, Hill A, Vernazza P, Monforte A, Antunes F, Staszewski S, Fox Z, Kaiser T, MaxCmin1 Trial Group. Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial. Journal of acquired immune deficiency syndromes (1999) 2005; 40:378-80.
Nov 1, 2005Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial
Nov 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:378-80
Tillmann Hans L, Lundgren Jens D, Dragsted Ulrik B, Hill Andrew, Vernazza Pietro, Monforte Antonella d'Arminio, Antunes Francesco, Staszewski Schlomo, Fox Zoe, Kaiser Thorsten, MaxCmin1 Trial Group
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
Rotger M, Telenti A, Rickenbach M, Bernasconi E, Drechsler H, Vernazza P, Furrer H, Günthard H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. The Journal of infectious diseases 2005; 192:1381-6.
Oct 15, 2005Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
Oct 15, 2005The Journal of infectious diseases 2005; 192:1381-6
Rotger Margalida, Telenti Amalio, Rickenbach Martin, Bernasconi Enos, Drechsler Henning, Vernazza Pietro, Furrer Hansjakob, Günthard Huldrych F, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients
Ferguson N, Mayer S, Lapins D, Vernazza P, Rode R, Bartley L, Fraser C, Ghani A, Hooper J, Donnelly C, Anderson R. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. Journal of the Royal Society, Interface / the Royal Society 2005; 2:349-63.
Sep 22, 2005Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients
Sep 22, 2005Journal of the Royal Society, Interface / the Royal Society 2005; 2:349-63
Ferguson N M, Mayer S L, Lapins D, Vernazza Pietro, Rode R A, Bartley L M, Fraser C, Ghani A C, Hooper J, Donnelly C A, Anderson R M
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72.
Aug 1, 2005Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Aug 1, 2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Perrin Luc, Ledergerber Bruno, Furrer Hansjakob, Swiss HIV Cohort Study
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
Rauch A, Furrer H, Evison J, Zinkernagel A, Bernasconi E, Vernazza P, Bucher H, Tarr P, Hirschel B, Weber R, Rickenbach M, Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:395-402.
Aug 1, 2005Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
Aug 1, 2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:395-402
Rauch Andri, Furrer Hansjakob, Evison John, Zinkernagel Annelies S, Bernasconi Enos, Vernazza Pietro, Bucher Heiner C, Tarr Philip E, Hirschel Bernard, Weber Rainer, Rickenbach Martin, Swiss HIV Cohort Study
Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Fehr J, Battegay M, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33:249-56.
Aug 1, 2005Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Aug 1, 2005Infection 2005; 33:249-56
Fehr J S, Battegay M, Spirig R, Jäger H, Vernazza Pietro, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. The Journal of infectious diseases 2005; 191:1419-26.
May 1, 2005Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
May 1, 2005The Journal of infectious diseases 2005; 191:1419-26
Tarr Philip E, Telenti Amalio, Ledergerber Bruno, Rickenbach Martin, Darioli Roger, Bernasconi Enos, Vernazza Pietro, Weber Rainer, Battegay Manuel, Hirschel Bernard, Martinez Raquel, Rotger Margalida, Furrer Hansjakob, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Impact of pregnancy and menopause on CD4 cell counts
van Benthem B, Vernazza P, Coutinho R, Prins M. Impact of pregnancy and menopause on CD4 cell counts. Journal of acquired immune deficiency syndromes (1999) 2005; 38 Suppl 1:S22.
Mar 1, 2005Impact of pregnancy and menopause on CD4 cell counts
Mar 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 38 Suppl 1:S22
van Benthem Bikgit H B, Vernazza Pietro, Coutinho Roel A, Prins Maria
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33:25-9.
Feb 1, 2005Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial
Feb 1, 2005Infection 2005; 33:25-9
Huber M, Weber R, Oppliger R, Vernazza Pietro, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner E L
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Weber R, Rickenbach M, Bucher H. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy 2005; 10:73-81.
Jan 1, 2005Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
Jan 1, 2005Antiviral therapy 2005; 10:73-81
Young Jim, Battegay Manuel, Vernazza Pietro, Tarr Philip E, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Weber Rainer, Rickenbach Martin, Bucher Heiner C